Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

PD-L1 affinity peptide with anti-tumour activity and application for same

A technology of PD-L1 and anti-tumor activity, which is applied in the application of this peptide, and the field of PD-L1 affinity peptide, can solve the problems of poor curative effect and achieve the effect of large lethality and good anti-tumor activity

Active Publication Date: 2013-09-18
ZHENGZHOU UNIV
View PDF2 Cites 34 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the process of tumor immunotherapy, negative co-stimulatory molecules mainly mediate immune tolerance and escape, and the biggest challenge encountered in the process of tumor immunotherapy is the poor efficacy caused by tumor immune tolerance and escape

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • PD-L1 affinity peptide with anti-tumour activity and application for same
  • PD-L1 affinity peptide with anti-tumour activity and application for same
  • PD-L1 affinity peptide with anti-tumour activity and application for same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] The PD-L1 affinity peptide P1 with anti-tumor activity described in the present invention is a polypeptide screened based on phage display peptide library technology. The amino acid sequence of the polypeptide P1 is: Phe-Pro-Asn-Trp-Ser-Leu- Arg-Pro-Met-Asn-Gln-Met; molecular weight 1520.7.

[0017] The experimental method and result involved in the present invention are as follows:

[0018] 1. ELISA identification of affinity between P1 phage monoclonal and PD-L1

[0019] The solid-phase screening method was used to screen the phage display 12-peptide library. After 5 rounds of screening, phage monoclonals with affinity to the extracellular domain of the target protein PD-L1 were enriched round by round, and the recovery rate increased by about 1000 times. Then 50 monoclonal phage coeruleus were randomly selected from the plates of the 4th and 5th rounds of screening, and their affinity was identified by ELISA. Among them, 17 were obviously positive, and the positiv...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a PD-L1 affinity peptide P1 with anti-tumour activity, which is the polypeptide obtained by phage display peptide library screening, wherein the amino acid sequence thereof is FPNWSLRPMNQM, and the molecular weight thereof is1520.7. The affinity peptide P1 with anti-tumour activity and aiming at a PD-L1 target disclosed by the invention has the advantage of being screened with a high flux by utilizing a phage display peptide library screening technology for the first time; and via an in-vivo tumour-bearing experiment for Kunming mice, the affinity peptide P1 disclosed by the invention is proved to have a great anti-tumour activity, can induce the internal tumour cell apoptosis of mice, and have an extremely high killing capacity for tumour cells. Via the affinity peptide P1 disclosed by the invention, new thoughts and theoretical basis are provided for research and development on medicines based on PD-L1.

Description

technical field [0001] The present invention relates to an active peptide, in particular to a PD-L1 affinity peptide with anti-tumor activity, and also relates to the application of the peptide. Background technique [0002] In recent years, with the continuous improvement of clinical diagnosis, surgical treatment, chemotherapy and radiotherapy, some tumor patients have been detected and treated early, and have achieved a better prognosis. However, finding new treatment methods and therapeutic drugs has always been a research hotspot worldwide. Compared with traditional treatment methods, tumor immunotherapy can activate or induce tumor patients to establish a specific immune response to tumor antigens, eliminate primary tumor cells, and establish immune memory to prevent tumor recurrence and metastasis. In the process of tumor immunotherapy, CD8 + Cytotoxic T lymphocytes (CTL) are the main effector cells of anti-tumor immunotherapy, CD8 + CTL needs to be activated thr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08A61K38/10A61P35/00
Inventor 高艳锋陈艳平祁元明刘蓓媛
Owner ZHENGZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com